share_log

Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals With Overweight Rating, Announces Price Target of $35

Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals With Overweight Rating, Announces Price Target of $35

Stephens & Co.啓動對催化製藥公司的覆蓋,給予超額評級,宣佈目標股價爲35美元
Benzinga ·  2024/11/18 23:28  · 評級/大行評級

Stephens & Co. analyst Sudan Loganathan initiates coverage on Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Overweight rating and announces Price Target of $35.

Stephens & Co. 分析師蘇丹·洛根納桑對catalyst pharmaceuticals(納斯達克:CPRX)首次進行覆蓋,給予超配評級,並宣佈價格目標爲35美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論